These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 11801536)

  • 1. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.
    Scharenberg CW; Harkey MA; Torok-Storb B
    Blood; 2002 Jan; 99(2):507-12. PubMed ID: 11781231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of ABCG2 expression and side population properties in human pluripotent stem cells.
    Zeng H; Park JW; Guo M; Lin G; Crandall L; Compton T; Wang X; Li XJ; Chen FP; Xu RH
    Stem Cells; 2009 Oct; 27(10):2435-45. PubMed ID: 19670287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1.
    Shimano K; Satake M; Okaya A; Kitanaka J; Kitanaka N; Takemura M; Sakagami M; Terada N; Tsujimura T
    Am J Pathol; 2003 Jul; 163(1):3-9. PubMed ID: 12819005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.
    Abbott BL
    Hematol Oncol; 2003 Sep; 21(3):115-30. PubMed ID: 14579240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line.
    Christgen M; Ballmaier M; Bruchhardt H; von Wasielewski R; Kreipe H; Lehmann U
    Mol Cell Biochem; 2007 Dec; 306(1-2):201-12. PubMed ID: 17660947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.
    Zhou S; Zong Y; Lu T; Sorrentino BP
    Biotechniques; 2003 Dec; 35(6):1248-52. PubMed ID: 14682060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCG2 expression is correlated neither to side population nor to hematopoietic progenitor function in human umbilical cord blood.
    Alt R; Wilhelm F; Pelz-Ackermann O; Egger D; Niederwieser D; Cross M
    Exp Hematol; 2009 Feb; 37(2):294-301. PubMed ID: 19101070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
    Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
    Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
    Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.